To receive the Femtech World newsletter, sign up here.
News
Endometriosis saliva test wins support of French authorities
The test is aimed at diagnosing patients clinically suspected of endometriosis
The French National Authority for Health (HAS) has deemed a saliva test for endometriosis “promising” after carrying out its own clinical testing, in a move that could lead to the test being 100 per cent reimbursed for eligible patients.
The French health authorities will allow early access to the diagnostic test as part of a scheme as it collects more data on the test’s effectiveness.
The Endotest, developed by the French biotech company Ziwig, works by measuring levels of certain biomarkers that are present in the saliva of women with endometriosis, aiming to provide a reliable diagnosis of the disease within seven days.
The device, which was validated as a diagnostic tool for endometriosis last year following a study published in the NEJM Evidence journal, could mark a major advance in the diagnosis of the condition, which affects roughly 190 million women and girls of reproductive age worldwide.
Yahya El Mir, founder of Ziwig, said: “This is an important moment for women suffering from endometriosis, a disease that is often difficult to diagnose.
“Ziwig Endotest promises a reliable, rapid and non-invasive diagnosis, dramatically reducing diagnostic wandering for thousands of patients.
“The test stands out as a non-invasive approach due to its breakthrough technology combining RNA analysis and artificial intelligence.
“This technology offers an alternative to traditional diagnostic processes, which are often lengthy, operator-dependent and invasive and provides fast and reliable results.”
The recognition by the HAS, Ziwig said, is a testimony to the potential of its technology, which is not limited to endometriosis.
The company said: “Our aim is to develop salivary diagnostics for other gynaecological pathologies, as well as in the fields of oncology and neurology, based on this same innovative technology.”
The Endotest is currently available in the UK, Switzerland, Italy, Germany, Sweden, Norway, Denmark, Iceland, Lithuania, Latvia, Estonia, Saudi Arabia and the United Arab Emirates.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Wellness4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






